Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Vascugel for Hemodialysis Access
NCT00479180Phase 2Completed
- Sponsor
- Pervasis Therapeutics
- Start
- Jul 2006
- Primary completion
- Jun 2010
- Modality
- Hydrogel Systems, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Vascugel in hemodialysis vascular access failure (4 arms), sponsored by Pervasis Therapeutics. Primary endpoint: Safety of vascugel at 3 years. Started Jul 2006; status: completed.
02
Drugs
Vascugel
03
Conditions
hemodialysis vascular access failure
Beyond the preview
Go deeper on NCT00479180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00479180.